Comparing Efficacy of Different Drugs Combinations for Serratus Anterior Block for Thoracotomy
NCT ID: NCT05565235
Last Updated: 2022-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
78 participants
INTERVENTIONAL
2022-12-09
2023-11-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objectives:
To compare bupivacaine alone, bupivacaine/magnesium and bupivacaine /nalbuphine in serratus anterior plane block for intraoperative and postoperative analgesia for thoracotomy surgery.
* The time for 1st rescue analgesia.
* Calculation of the opioid requirements; (the total intra-operative post-operative morphine consumption in first 24h postoperative).
* Assessment of pain score (VAS)- rest, VAS-movement, VAS-cough during post-operative 24hrs period.
Hypothesis:
We hypothesize that magnesium sulfate and nalbuphine can reduce acute postoperative pain and result in efficacious postoperative analgesia due to block of the lateral cutaneous branches of the intercostal nerves (T2 - T6) by diffusion across the inter-fascial planes.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group BN: patients will receive intraoperative serratus block with bupivacaine /nalbuphine.
V. Study Procedures
1. Randomization:
The patients will be randomized using a computer-generated list of random numbers which will be sealed in closed envelopes. Patients will be randomly allocated to one of the three groups. The study drugs are going to be prepared by anesthetist (who were blinded to the study and did not share in the technique) in labelled syringes, patients into 3 groups by a sealed opaque envelope, and received the study drug as follows: group B (n = 26): (bupivacaine): received bupivacaine 30 mL 0.25%, group BMG (n =26): received bupivacaine 30 mL 0.25% and 500 mg magnesium sulphate. Group BN (n =26): (bupivacaine/nalbuphine): received bupivacaine 30 mL 0.25 % and nalbuphine 0.2 mg/kg.
2. Study Protocol All patients will be assessed clinically and investigated for exclusion of any of the above-mentioned contraindications.
Laboratory work needed will be: Complete blood count (CBC); prothrombin time and concentration (PT\& PC, INR), renal functions and liver function tests or other necessary investigation for the desired surgery. ECG, CXR, CT chest and echocardiography will be done if needed preoperatively Anesthetic application
* Standard monitoring procedures will include continuous ECG, pulse oximetry, invasive arterial blood pressure, end-tidal CO2, inhaled gas analyzer and temperature monitoring. Baseline readings (T0) of heart rate, systolic, diastolic, and mean blood pressure are going to be record after monitor attachment and every 30 min
* General anesthesia will be induced in all groups (B, BN, AND BMG group) using fentanyl 2 mic/kg, propofol 2 mg/kg and atracurium 0.5 mg/kg while in obese patients Lean body weight (LBW) will be used. single or double lumen tube will be used as preferred by surgeon, Anesthesia will be maintained using isoflurane (1 MAC) and atracurium supplements were given to maintain muscle relaxation., diclofenac 75mg once iv infusion and acetaminophen 15 mg/kg. Additional dose of fentanyl 1mic / kg will be given if there is tachycardia \>100 or intraoperative hypertension more than 20% of the preoperative value. In addition to, all patients will receive cefotaxime 50 mg/kg.
Near the end of surgery, the surgeon is going to aspirate the content of the labelled syringes with a sterile one and ask to inject it below the serratus anterior muscle after closing it. To prevent inadvertent intravascular insertion of the needle, the study drugs are going to be injected in increments after repeated aspiration. At the end of the surgery, inhaled anesthetic is going to discontinue. After the reversal of muscle relaxation and full recovery, patients will be monitored at the recovery unit. Postoperative pain Visual Analogues Scales (VAS, VAS movement, VAS cough) are going to be measure pain (static, dynamic and with cough respectively), where 0 = "no pain" and 10 = "worst pain imaginable", at 1, 6, 12, 24 h by a person not oriented by protocol. Classic postoperative analgesic regimen (Diclofenac 75mg every 8hrs and acetaminophen 1gm every 6 hrs.). The efficacy of the block will be test by measuring the distribution of lost cold sensation along distribution of lateral cutaneous nerve from second intercostal to ninth intercostal nerve.
Morphine 2 mg Iv incremental boluses will be given as rescue analgesia for patients if VAS score \>3.
1\. Measurement tools
* Demographic data (age, sex, BW) patient surgery characteristic (duration of the surgery, type of operation) and ASA status will be recorded.
* In the PACU and the ward, patient will be assessed for the first 24 hours post-operative period using (VAS score) for Pain assessment.
Blood pressure (SBP, DBP and MAP) and heart rate will also be recorded during the operation and the first 24 hours post-operative period and intraoperative fentanyl doses.
Statistical Analysis I. Sample size The time of 1st use of rescue analgesia post-operatively is defined as the primary outcome of the study using one-way ANOVA test. As based on previous study (Comparison of ultrasound-guided serratus plane block and thoracic paravertebral block for postoperative analgesia after thoracotomy, a randomized controlled trial Research and Opinion in Anesthesia \& Intensive Care 2018, 5:314-322), the mean time to 1st use of morphine was (6.2 ± 1.66) hours.
If combining the bupivacaine with nalbuphine or with magnesium would result in a 30% increase in the time to 1st use of morphine: α error of 0.05 and power of 0.95. A minimum of 78 patients was calculated (27 patients in each group). sample size was calculated using G-Power version 3.1.9.2 software.
II. Statistical analysis
Analysis of data will be performed using Statistical package for social science (SPSS) software, version 15 for Microsoft Windows (SPSS Inc., Chicago, IL, and USA). Categorical data will be reported as numbers and percentages and will be analyzed using chi-squared test. Continuous data will be checked for normality using Kolmogorov-Smirnov test. Normally distributed data will be presented as means (standard deviations) and will be analyzed using unpaired student t-test. Skewed data will be expressed as medians (quartiles) and will be analyzed using Mann Whitney U test. For repeated measures, a two-way repeated measure ANOVA will be used to evaluate the block (between-groups factor) and the time (repeated measures)". Post-hoc pairwise comparison will be performed using Bonferroni test. P value of 0.05 or less will be considered significant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group B
bupivacaine
patients will receive intraoperative serratus block with bupivacaine
no additives
Group BMG
bupivacaine/ magnesium.
serratus block with bupivacaine /magnesium
magnesium added
Group BN
bupivacaine /nalbuphine.
serratus block with bupivacaine with nalbuphine
nalbuphine added
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
patients will receive intraoperative serratus block with bupivacaine
no additives
serratus block with bupivacaine /magnesium
magnesium added
serratus block with bupivacaine with nalbuphine
nalbuphine added
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with American Society of Anesthesiology ASA I, II or III.
Exclusion Criteria
2. Contraindication for regional anesthesia
* Allergy from local anesthetics
* Bleeding diathesis (Bleeding tendency with prothrombin concentration PC less than 75 % or platelet count less than 50,000/µL.
* Use of anticoagulants, infection at the puncture site.
3. Presence of severe Chronic renal impairment or acute renal failure, decompensated liver disease, cardiac or psychiatric disorders, GIT ulcers, communication barriers, hearing deficit or high grades of visual deficit that interfere with consenting, VAS assessments, and delirium, or another cognitive dysfunction.
4. Patient intubated preoperatively.
5. Patient will not be extubated immediately postoperatively
6. Opioid tolerant patients.
7. Any contraindications of Magnesium infusion as hypovolemia or severe impaired ventricular systolic function.
8. Contraindication of acetaminophen and Diclofenac sodium administration.
16 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Hussein Sayed Hasan
lecturer of anesthesia , surgical ICU and pin managment
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tamer M. Atteya, M.D
Role: STUDY_CHAIR
Lecturer of anesthesia,surgical ICU and pain managment
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr Alainy
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ahmed H. Sayed, M.D
Role: primary
Tamer M. Atteya, M.D
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Gerner P. Postthoracotomy pain management problems. Anesthesiol Clin. 2008 Jun;26(2):355-67, vii. doi: 10.1016/j.anclin.2008.01.007.
Kavanagh BP, Katz J, Sandler AN. Pain control after thoracic surgery. A review of current techniques. Anesthesiology. 1994 Sep;81(3):737-59. doi: 10.1097/00000542-199409000-00028. No abstract available.
Katz J, Jackson M, Kavanagh BP, Sandler AN. Acute pain after thoracic surgery predicts long-term post-thoracotomy pain. Clin J Pain. 1996 Mar;12(1):50-5. doi: 10.1097/00002508-199603000-00009.
Kaushal B, Chauhan S, Saini K, Bhoi D, Bisoi AK, Sangdup T, Khan MA. Comparison of the Efficacy of Ultrasound-Guided Serratus Anterior Plane Block, Pectoral Nerves II Block, and Intercostal Nerve Block for the Management of Postoperative Thoracotomy Pain After Pediatric Cardiac Surgery. J Cardiothorac Vasc Anesth. 2019 Feb;33(2):418-425. doi: 10.1053/j.jvca.2018.08.209. Epub 2018 Aug 31.
Semyonov M, Fedorina E, Grinshpun J, Dubilet M, Refaely Y, Ruderman L, Koyfman L, Friger M, Zlotnik A, Klein M, Brotfain E. Ultrasound-guided serratus anterior plane block for analgesia after thoracic surgery. J Pain Res. 2019 Mar 11;12:953-960. doi: 10.2147/JPR.S191263. eCollection 2019.
De Oliveira GS Jr, Castro-Alves LJ, Khan JH, McCarthy RJ. Perioperative systemic magnesium to minimize postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology. 2013 Jul;119(1):178-90. doi: 10.1097/ALN.0b013e318297630d.
Chawda PM, Pareek MK, Mehta KD. Effect of nalbuphine on haemodynamic response to orotracheal intubation. J Anaesthesiol Clin Pharmacol. 2010 Oct;26(4):458-60.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N-50-2022
Identifier Type: -
Identifier Source: org_study_id